Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Ozempic
Novo Nordisk CEO: “We can’t solve the problem of expensive medicine alone”
While both Danes and the Danish government seem pleased with Novo Nordisk and the company’s enormous earnings, the large pharmaceutical company is not so popular in the US.Slimming drugs Wegovy and Ozempic are popular there too,
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Opinion
Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag
Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.
1d
Novo Nordisk is bigger than Denmark's economy — but the prime minister isn't worried about another Nokia
Denmark Prime Minister Mette Frederiksen downplayed concerns that Ozempic maker Novo Nordisk (NVO), the Scandinavian nation’s ...
EconoTimes
1d
Denmark’s PM Downplays Concerns Over Novo Nordisk’s Dominance Amid Economic Growth Surge
Denmarks Prime Minister, Mette Frederiksen, rejected concerns over the economic risks posed by Novo Nordisks rapid growth.
20h
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Looking at options history for Novo Nordisk NVO we detected 11 trades. If we consider the specifics of each trade, it is ...
2d
Denmark’s Premier Brushes Off Risk as Novo Outgrows Economy
Danish Prime Minister Mette Frederiksen said she’s “extremely proud” of the country’s corporate champions, and rejected ...
2d
Novo Nordisk A/S - share repurchase programme
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
4d
on MSN
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
4d
on MSN
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
4d
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback